A retrospective analysis identified a female patient [age at onset not clearly stated] who developed gastrointestinal side effects while receiving miglustat. The girl had been diagnosed with Niemann-Pick disease type C at 14 years of age. She started receiving substrate reduction therapy with miglustat 600 mg/day [route not stated]. She experienced gastrointestinal side effects [time to reaction onset not stated]. Her miglustat dosage was decreased to 200 mg/day. …